#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell small lymphocytic lymphoma Pemphigoid Microscopic polyangiitis Progressive familial intrahepatic cholestasis Angiosarcoma recurrent Pituitary-dependent Cushing's syndrome Transitional cell carcinoma Adenoid cystic carcinoma Progressive multifocal leukoencephalopathy Anti-neutrophil cytoplasmic antibody positive vasculitis Human papilloma virus immunisation Exudative retinopathy Idiopathic inflammatory myopathy Niemann-Pick disease Restless legs syndrome More trials…

    Learn about Rare Diseases

    Chondrosarcoma metastatic – Treatment Glycogen storage disease type II – Trials in Disease Cholangitis sclerosing Langerhans cell sarcoma – Trials in Disease Hereditary hypophosphataemic rickets SAPHO syndrome – Diagnostics Haemophilia B with anti factor IX – Diagnostics Retinoblastoma – Life with Disease Glycogen storage disease type II Netherton’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ontasameran Anhydrous Cidofovir Aciclovir Valproic Acid UDONITRECTAG Ascorbic Acid Bp Procarbazine Hydrochloride IM-101 Ecoo2 Skin Autograft Anakinra Cd7-Cart01 Sasanlimab Apremilast Maribavir WEF-001 Sodium Glycocholate Sonelokimab Treprostinil Sodium Dalteparin Sodium More therapies…

    Learn about Your Condition

    Retinal artery occlusion Arteriovenous graft thrombosis Eye inflammation Primary hyperthyroidism Labour pain Osteochondrodysplasia Cardiac arrest Obstructive pancreatitis Organ donor Arterial disorder Coronary artery bypass Hypophosphatasia Fibrosarcoma metastatic Aphthous ulcer Noninfective chorioretinitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Amivantamab
    • Bevacizumab
    • Cetuximab
    Belgium France Germany Hungary Italy The Netherlands +4

  • Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

    Recruiting

    3 1
    Investigated Drugs:
    • TIFCEMALIMAB
    • Toripalimab
    Belgium France Germany Italy The Netherlands Poland +2

  • Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Elacestrant
    • Exemestane
    Austria Belgium Czechia Denmark Finland France +9

  • Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Olaparib
    • Bevacizumab
    • Carboplatin
    Italy

  • Study Comparing Gemcitabine and Paclitaxel with Drug Combination for Patients with Advanced Pancreatic Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine Hydrochloride
    Italy

  • Study of Roginolisib for Patients with Advanced Uveal Melanoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Roginolisib
    • Dacarbazine Citrate
    • Relatlimab
    Italy Spain

  • Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Treosulfan
    • Daunorubicin Hydrochloride
    • Gemtuzumab Ozogamicin
    Italy

  • Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • VERT-002
    Belgium France Germany Italy The Netherlands Spain

  • Study on Atezolizumab for Patients with Malignant Pleural Mesothelioma After Surgery

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Atezolizumab
    Italy

  • Study on Aspirin and Metformin for Patients with Locally Advanced Rectal Cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Colorectal cancer stage II
    • Colorectal cancer stage III
    Investigated Drugs:
    • Carbasalate Calcium
    • Metformin Embonate
    • Capecitabine
    Italy
Previous Page
1 … 7 8 9 10 11 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!